Antigen cd19. Medical search. Frequent questions

A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors. (escholarship.org)
Chimeric Antigen Receptors (CARs) consist of the antigen-recognition portion of a monoclonal antibody fused to an intracellular signaling domain capable of activating T-cells. (escholarship.org)
Adoptive T-cell therapy with T cells expressing chimeric antigen receptors (CARs) is an active area of cancer research. (ashpublications.org)
One way to achieve this is to genetically modify immune cells, mainly T cells and recently also natural killer (NK) cells, to express chimeric antigen receptors (CARs). (nature.com)
Chimeric antigen receptor T cells (CARTs) are a novel cell-based therapy designed to direct host-derived T-cells against cancer cells through tumor-specific surface receptors. (medpagetoday.com)
The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. (thermofisher.com)
Chimeric antigen receptors (CARs) endow T cells with antigen-specific recognition, activation, and proliferation independent of major histocompatibility complex ( 1 - 3 ). (snmjournals.org)

Of note, CD19, CD20, CD30, CD33, CD123, and CD269 as ideal targets have shown extraordinary potential for CAR-T cell therapy and other targets such as CD23 and SLAMF7 have brought promising future for clinical trials. (hindawi.com)
Currently approved CAR-T therapies use CD19 and CD20 as targets. (cancer.org)
PHILADELPHIA - Bispecific anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy was well tolerated and showed signs of clinical efficacy in patients with relapsed/refractory B-cell lymphoma, according to phase I clinical trial data presented during Week 1 of the virtual AACR Annual Meeting 2021 , held April 10-15. (aacr.org)
In this study, Ghafouri and colleagues evaluated the safety and efficacy of anti-CD19/CD20 bispecific CAR T-cells using naïve memory cells. (aacr.org)
The presented analysis included five patients with B-cell malignancies that were positive for both CD19 and CD20 tumor antigen expression. (aacr.org)
Naïve memory T cells were extracted from each patient, engineered to express an anti-CD19/CD20 CAR, expanded, and infused back into the patient at one of two different doses (either 5×10 7 cells or 2×10 8 cells). (aacr.org)
The patient whose cancer did not respond to treatment had early disease progression with CD19/CD20-negative disease by day 14 after infusion. (aacr.org)
Although long-term follow-up and analysis of additional patients are needed, our results indicate that bispecific anti-CD19/CD20 CAR in naïve memory T cells may be safe and effective in patients with relapsed or refractory B-cell lymphomas," Ghafouri said. (aacr.org)
We are pleased to have treated the first patient with IMPT-314 and build on the clinical evidence from the ongoing investigator-led study of this dual-targeted CD19/CD20 CAR T-cell therapy. (mystateline.com)
We designed this therapy to target both CD19 and CD20 to help restrict antigen escape and ultimately prolong treatment response. (mystateline.com)
IMPT-314 is a CD19/CD20-targeting chimeric antigen receptor (CAR) T-cell therapy that utilizes a potent bispecific CAR and a 4-1BB costimulatory domain. (mystateline.com)

Clinical trials are in progress assessing the use of mature T-lymphocytes transduced with CARs targeting CD19 antigen to treat B-lineage malignancies. (escholarship.org)
CD19 is an attractive target for immunotherapy because of its consistent and specific expression in most of the stages of maturation and malignancies of B-lymphocyte origin, but not on hematopoietic stem cells. (escholarship.org)
Adoptive T-cell therapy with anti-CD19 chimeric antigen receptor (CAR)-expressing T cells is a new approach for treating advanced B-cell malignancies. (ashpublications.org)
12 , 13 Clinical trials in which patients with advanced B-cell malignancies receive T cells expressing anti-CD19 CARs are in early stages, and it is not known whether adoptive transfer of T cells targeting this self-antigen will be an effective therapy for B-cell malignancies. (ashpublications.org)
Adoptive cell therapy (ACT) with chimeric antigen receptor T (CAR-T) cells can restore the activity of exhausted T cell through reprogramming and is widely used in the treatment of relapsed/refractory (r/r) hematological malignancies. (hindawi.com)
Related studies have reported that the complete response rate of CD19-CAR-T cells in hematological malignancies is approximately 88-90% [ 13 , 14 ]. (hindawi.com)
CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. (ajmc.com)
Chimeric antigen receptor (CAR) T-cell therapy is an example of how immunotherapy is revolutionizing the treatment of hematologic malignancies with unprecedented response rates in patients with relapsed/refractory lymphoma, multiple myeloma, and acute lymphoblastic leukemia. (ajmc.com)
Chimeric antigen receptor T cells for gamma-delta T cell malignancies. (ucl.ac.uk)
Successful treatment of B-cell malignancies with CD19-CAR T cells was a milestone for this approach ( 4 , 5 ). (snmjournals.org)
The Food and Drug Administration (FDA) has received reports of T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies such as idecabtagene vicleucel injection. (medlineplus.gov)

An exception was long-lived CAR-T cells in two adult individuals with a different cancer-chronic lymphocytic leukemia (CLL)-in whom anti-CD19 CAR-T cells have persisted for almost a decade thus far 7 . (nature.com)

ELISA assays using several different monoclonal antibodies to CD19 demonstrated dose-related specific binding by the fusion molecule CD19sIg1-4, but no binding by CD19sIg1-3. (escholarship.org)
This fusion molecule is a sensitive reagent for detection of anti-CD19 CAR derived from any monoclonal antibody present in CAR-modified T-cells. (escholarship.org)
Cd19 Test (B-lymphocyte antigen CD19, CD19 molecule) in Kasargod at Rs. (bajajfinservhealth.in)
Two children with relapsed and refractory pre-B-cell ALL received infusions of T cells transduced with anti-CD19 antibody and a T-cell signaling molecule (CTL019 chimeric antigen receptor T cells), at a dose of 1.4×10(6) to 1.2×10(7) CTL019 cells per kilogram of body weight. (nih.gov)
B-lymphocyte antigen CD19, also known as CD19 molecule (Cluster of Differentiation 19), B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12 and CVID3 is a transmembrane protein that in humans is encoded by the gene CD19. (wikipedia.org)
The CD19 molecule is expressed on 100% of the peripheral B cells as defined by expression of kappa or lambda light chains. (thermofisher.com)

The emergence of tumor cells that no longer express the target indicates a need to target other molecules in addition to CD19 in some patients with ALL. (nih.gov)
A low dose (approximately 1.5×10(5) cells per kilogram of body weight) of autologous chimeric antigen receptor-modified T cells reinfused into a patient with refractory chronic lymphocytic leukemia (CLL) expanded to a level that was more than 1000 times as high as the initial engraftment level in vivo, with delayed development of the tumor lysis syndrome and with complete remission. (nih.gov)
Apart from the tumor lysis syndrome, the only other grade 3/4 toxic effect related to chimeric antigen receptor T cells was lymphopenia. (nih.gov)
CAR-expression on T or NK cells allows them to specifically target cancer cells via recognition of tumor associated antigens. (nature.com)
Binding of a tumor antigen via the scFv activates the T cell in a major histocompatibility-independent manner which leads to a cytotoxic response [ 3 ]. (nature.com)
The addition of separate adapter molecules (AMs) specific for tumor antigens and CAR-immune cells targeting these AMs allows a more precise and temporally limited therapy. (nature.com)
Thereby, several antigens can be targeted at once and the therapy can be adapted in case antigen-loss tumor variants appear. (nature.com)
Research has intensified to understand ERV protein function and their role as tumor antigens and targets for cancer (immune) therapy. (frontiersin.org)
This study supports ERV-K env as a single prognostic indicator for better survival of RCC, which we propose represents a new tumor antigen. (frontiersin.org)
The BAFF-R-CAR T cells also killed CD19-negative tumor cells isolated from 4 patients with leukemia who relapsed after being treated with a CD19-targeting antibody, and extended survival in mice that were implanted with cells from a fifth relapsed patient. (ajmc.com)
Anti-CD19 CAR T-cell therapy has revolutionized the management of this disease in recent years, but it still has several limitations," she noted, explaining that approximately half of patients relapse within six months of starting the treatment due to a lack of CAR T-cell persistence and/or downregulation of the target antigen, CD19, on the tumor. (aacr.org)
Bispecific CAR T cells target two tumor antigens at once and have been explored as a strategy to reduce the risk of relapse. (aacr.org)
We hypothesized that this approach might increase CAR T-cell persistence and expansion in the patient, while limiting relapses due to loss of the tumor antigen. (aacr.org)
Several types of ACT round out the immunotherapy arsenal, including chimeric antigen receptor (CAR) T-cell therapy, T-cell receptor (TCR) therapy, and tumor-infiltrating lymphocyte (TIL) therapy. (aacr.org)
These strategies rely on the isolation of T cells, which are either genetically modified to target tumor-specific antigens or are expanded from an endogenous population that recognizes tumor neoantigens. (aacr.org)

Chimeric antigen receptor-modified T cells with specificity for CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL). (nih.gov)
We designed a lentiviral vector expressing a chimeric antigen receptor with specificity for the B-cell antigen CD19, coupled with CD137 (a costimulatory receptor in T cells [4-1BB]) and CD3-zeta (a signal-transduction component of the T-cell antigen receptor) signaling domains. (nih.gov)
Yet, if and how the tissue environment shapes the antigen specificity of iNKT cells remains unknown. (elifesciences.org)

Chimeric antigen receptor-modified T cells are capable of killing even aggressive, treatment-refractory acute leukemia cells in vivo. (nih.gov)

In this study, we systematically analyzed CD19 CAR-T cells of 10 children with R/R B-ALL enrolled in the CARPALL trial via high-throughput single-cell gene expression and T cell receptor sequencing of infusion products and serial blood and bone marrow samples up to 5 years after infusion. (nature.com)
We studied 15 consecutive patients with high-risk or relapsed CD19 + B-ALL treated with CD19 CAR-T cell therapy on the CARPALL study ( NCT02443831 ) and in whom adequate CAR-T cells could be isolated for subsequent analyses from cryopreserved samples of blood or bone marrow. (nature.com)
Engineered cells persisted at high levels for 6 months in the blood and bone marrow and continued to express the chimeric antigen receptor. (nih.gov)
A specific immune response was detected in the bone marrow, accompanied by loss of normal B cells and leukemia cells that express CD19. (nih.gov)
Analysis of mixed bone marrow chimeras suggest that prior to an initial antigen encounter, CD19 promotes the survival of naive recirculating B cells and increases the in vivo life span of B cells in the peripheral B cell compartment. (wikipedia.org)

GC012F is an autologous CAR-T therapeutic candidate dual-targeting B cell maturation antigen (BCMA) and CD19, and utilizes Gracell's proprietary FasTCAR next-day manufacturing platform. (biospace.com)

CD19 forms a complex with CD21 (CR2) and CD81 (TAPA-1), and functions as a BCR co-receptor. (biolegend.com)
CD19, in association with CD21 and CD81, forms a molecular complex integral to B cell activation. (biolegend.com)
on the other, it works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. (wikipedia.org)
On the cell surface, CD19 is the dominant signaling component of a multimolecular complex including CD21, a complement receptor, CD81, a tetraspanin membrane protein (TAPA-1), and CD225. (wikipedia.org)

This medication targets CD19 which is a b-cell lymphocyte antigen that is present in some cancers. (oncolink.org)
This second-generation of CAR T targets an alternative surface marker called B cell activating factor receptor (BAFF-R). Scientists engineered CAR T cells to go after human lymphoma and acute lymphocytic leukemia cells expressing BAFF-R in vitro and in mouse models in comparison with CD19-directed CAR T cells. (ajmc.com)
GC012F simultaneously targets CD19 and BCMA to drive fast, deep and durable responses, which can potentially improve efficacy and reduce relapse in multiple myeloma and B-NHL patients. (biospace.com)

B-lineage acute lymphoblastic leukemia (B-ALL) is the most common type of childhood cancer and mostly derives from immature B cells that carry the cell surface antigen CD19 (ref. 1 ). (nature.com)
CD19 expression in mature B cells is threefold higher than that in immature B cells. (wikipedia.org)

The CAR T cells in this clinical trial were also designed to have 2 target antigens: CD19 and CD22. (cancer.net)

We believe GC012F has vast potential to meaningfully improve cancer care, including the faster delivery to patients enabled by Gracell's FasTCAR next-day manufacturing and a novel approach of BCMA and CD19 dual-targeting in multiple indications. (biospace.com)
GC012F is a FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T product candidate that is currently being evaluated in IIT studies in China for the treatment of multiple myeloma and B-cell non-Hodgkin's lymphoma. (biospace.com)

This suggests that unique tissue-specific factors (including local lipid antigens, cytokines and/or hormones) may shape the population of iNKT cells resident in those tissues, ultimately regulating local immune responses. (elifesciences.org)

cytokine blockade with etanercept and tocilizumab was effective in reversing the syndrome and did not prevent expansion of chimeric antigen receptor T cells or reduce antileukemic efficacy. (nih.gov)
The antilymphoma efficacy of anti-CD19-CAR-transduced T cells was critically dependent on irradiation of mice before anti-CD19-CAR-transduced T-cell infusion. (ashpublications.org)
Anti-CD19-CAR-transduced T cells had superior antilymphoma efficacy compared with the anti-CD19 monoclonal antibody from which the anti-CD19 CAR was derived. (ashpublications.org)

Follicular dendritic cells also express CD19. (thermofisher.com)

CD19 is involved in B cell development, activation, and differentiation. (biolegend.com)
CD19 is widely expressed during all phases of B cell development until terminal differentiation into plasma cells. (wikipedia.org)
The presence of a functional BCR is necessary during antigen-dependent differentiation and for continued survival in the peripheral immune system. (wikipedia.org)
Part of B cell differentiation is controlling c-MYC protein stability and steady-state levels through CD19, which acts as a PAX5 target and downstream effector of the PI3K-AKT-GSK3β axis. (wikipedia.org)

CD19 is a 95 kd Type I transmembrane glycoprotein in the immunoglobulin superfamily (IgSF) with two extracellular C2-set Ig-like domains and a relatively large, 240 amino acid, cytoplasmic tail that is highly conserved among mammalian species. (wikipedia.org)
During B cell lymphopoiesis, CD19 surface expression starts during immunoglobulin (Ig) gene rearrangement, which coincides during B lineage commitment from hematopoietic stem cell. (wikipedia.org)
The most active T cell endogenous inhibitory pathway is the immunoglobulin superfamily such as CD28/cytotoxic T lymphocyte antigen-4 (CTLA-4): B7-1/B7-2 receptor/ligand grouping, which plays a central role in coordinating immune responses [ 7 , 8 ]. (hindawi.com)
CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. (thermofisher.com)

Most CARs that are being evaluated in current clinical and preclinical studies recognize self-antigens that are expressed by normal tissues as well as malignant cells. (ashpublications.org)
CD19 expression is restricted to normal mature B cells, malignant B cells, and B-cell precursors. (ashpublications.org)
CD19 is expressed on all normal, mitogen-stimulated, and malignant B cells, excluding plasma cells[inconsistent]. (wikipedia.org)
Blinatumomab is a bispecific T-cell engager (BiTE) targeting CD19 on malignant B cells and CD3 on normal host T cells. (hindawi.com)
The receptor for CD19 is an important functional regulator of normal and malignant B cell proliferation, and is expressed in all B cell precursor leukemias. (thermofisher.com)
Chimeric antigen receptor (CAR) T-cell therapy is designed to enhance the body's immune system to effectively kill malignant cells. (ajmc.com)

We propose to develop an innovative adaptive cellular immunotherapy (ACIT) utilizing Chimeric Antigen Receptor (CAR)-engineered T cells, which respond to both CD19+ cells and cytomegalovirus (CMV) antigen, namely CMV-CD19 bi-specific T cells, followed by CMV vaccine to further expand the T cells in vivo. (lls.org)

It remains to be established whether chimeric antigen receptor T cells have clinical activity in acute lymphoblastic leukemia (ALL). (nih.gov)
In the context of relapsed and refractory childhood pre-B cell acute lymphoblastic leukemia (R/R B-ALL), CD19-targeting chimeric antigen receptor (CAR)-T cells often induce durable remissions, which requires the persistence of CAR-T cells. (nature.com)
Results from a recent study from China showed that a new approach to chimeric antigen receptor (CAR) T-cell therapy was able to put B-cell acute lymphoblastic leukemia (ALL) into remission in many children with high-risk disease. (cancer.net)
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. (ucl.ac.uk)

The advent of CD19 chimeric antigen receptor (CAR)-T cell therapy in recent years has transformed the treatment of intractable ALL 2 . (nature.com)
To evaluate anti-CD19-CAR-transduced T cells in a murine model of adoptive T-cell therapy, we developed a CAR that specifically recognized murine CD19. (ashpublications.org)
Besides modification based on a second-generation CAR, more advanced CAR-immune cell therapeutics are being tested, which utilize precise insertion of genes to circumvent graft-versus-host disease (GvHD) or employ a dual targeting approach and adapter CARs in order to avoid therapy resistance caused by antigen loss. (nature.com)
[ 2 ] Options for second-line therapy in patients with relapsed/refractory disease include chemotherapy-free regimens with biologic targeted agents such as covalent Bruton tyrosine kinase (BTK) inhibitors, lenalidomide,venetoclax, and chimeric antigen receptor (CAR) T-cell therapy. (medscape.com)
Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma. (moffitt.org)
Chimeric antigen receptor (CAR) T-cell therapy can induce durable remissions and possibly cure patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with poor prognosis and no standard therapeutic options. (medpagetoday.com)
Adoptive cellular therapy, especially chimeric antigen receptor (CAR) T cell therapy, has gained unprecedented success among hematologic tumors [ 11 ]. (hindawi.com)
Kymriah is the first CAR-T therapy based on CD19 approved by the FDA in 2017 [ 12 ]. (hindawi.com)
Researchers said Wednesday they created a second-generation chimeric antigen receptor (CAR) T-cell therapy that prevented relapse of lymphoma and leukemia and led to 100% long-term survival in early laboratory studies. (ajmc.com)
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. (upenn.edu)
Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf. (upenn.edu)
204. Prior CD19 targeted therapy with the exception of subjects who received KTE-X19 or axicabtagene ciloleucel in this study and are eligible for re-treatment. (who.int)
205. Prior chimeric antigen receptor therapy or other genetically modified T cell therapy 206. (who.int)

CARs displayed on the surface of transduced cells perform non-MHC-restricted antigen recognition and activating intracellular signaling pathways for induction of target cytolysis, cytokine secretion and proliferation. (escholarship.org)
Furthermore, the so-called adapter CARs have been developed by splitting antigen recognition and CAR-immune cell activation. (nature.com)
By analysing iNKT cells from lymphoid tissues of mice and humans we demonstrate that their T cell receptor (TCR) repertoire is highly diverse and is distinct for cells from various tissues resulting in differential lipid-antigen recognition. (elifesciences.org)
Despite this prototypical TCR repertoire gene usage, in recent years it has become apparent that there are variations within the iNKT cell repertoire that ultimately impact the antigen recognition capacity and consequently the functional outcomes during an immune response. (elifesciences.org)

CD19 is a 95 kD type I transmembrane glycoprotein also known as B4. (biolegend.com)
Description: The HIB19 monoclonal antibody reacts with human CD19, a 95 kDa transmembrane glycoprotein. (thermofisher.com)

Anti-CD19-CAR-transduced T cells eradicated intraperitoneally injected lymphoma cells and large subcutaneous lymphoma masses. (ashpublications.org)
Those 2 products attack the target antigen CD19, but in some patients, relapse occurs when the lymphoma cells stop producing CD19. (ajmc.com)

Ultimately, CD19 expression is integral to the propagation of BCR-induced survival signals and the maintenance of homeostasis through tonic signaling. (wikipedia.org)

Flow cytometric analysis of CD19 expression on human peripheral blood leucocytes. (bdbiosciences.com)

Experiments using CD19 knockout mice found that CD19 is essential for B cell differentiative events including the formation of B-1, germinal center, and marginal zone (MZ) B cells. (wikipedia.org)
This Antibody was verified by Knockout to ensure that the antibody binds to the antigen stated. (thermofisher.com)
Knockout of CD19 was achieved by CRISPR-Cas9 genome editing using LentiArray™ Lentiviral sgRNA (Product # A32042, Assay ID CRISPR807388_LV) and LentiArray Cas9 Lentivirus (Product # A32064). (thermofisher.com)

Signaling through CD19 induces tyrosine phosphorylation, calcium flux and proliferation of B cells. (thermofisher.com)

The other patient had a relapse, with blast cells that no longer expressed CD19, approximately 2 months after treatment. (nih.gov)

In humans, CD19 is expressed in all B lineage cells. (wikipedia.org)
In humans, CD19 is encoded by the 7.41 kilobase CD19 gene located on the short arm of chromosome 16. (wikipedia.org)
iNKT cells have been traditionally defined by the expression of an invariant TCR α-chain (Vα14-Jα18 in mice or Vα24-Jα18 in humans) and their capacity to recognise the glycolipid antigen α-galactosylceramide (αGalCer) presented on CD1d. (elifesciences.org)

A specific reagent for the detection of anti-CD19 CAR expression was developed, a fusion protein consisting of human CD19 extracellular domains and the Fc region of human IgG1 (CD19sIg). (escholarship.org)

The first phase of in vitro experiments successfully synthesized and expressed in transfected cells the chimeric antigen receptor (CAR) construct targeting CD19 and NR2F6. (kdvr.com)

The proposed strategy is design to enhance proliferation, lengthen persistence and augment the anti-lymphoma activity of adoptively transferred CMV-CD19 CAR T cells. (lls.org)

Previously, we generated a novel low-affinity CAR incorporating a CD19-specific single-chain variable fragment (scFv) called CAT, displaying a faster off-rate of interaction than the FMC63 CD19 binder used in prior clinical studies 3 . (nature.com)

Conjugation of the CD19sIg1-4 fusion protein to Alexa Fluor 488 allowed specific and sensitive staining of anti-CD19 CAR-bearing cells for flow cytometry assays, detecting as low as 0.5% of CAR-modified primary cells with minimal background staining. (escholarship.org)
CD19 signaling, independent of BCR functions, increases c-MYC protein stability. (wikipedia.org)
CD19 signaling involves the recruitment and activation of phosphoinositide 3-kinase (PI3K) and later downstream, the activation of protein kinase B (Akt). (wikipedia.org)
This assessment can also be done by measuring antibody responses following active immunization with protein or polysaccharide antigens. (medscape.com)
In children who have completed immunizations with diphtheria, pertussis, and tetanus (DPT) or Hib-conjugated vaccines, the antibody response to protein antigens can be tested in adults and older children by measuring IgG antibodies to tetanus or diphtheria toxoid and H influenzae type b (Hib) polysaccharide antigen. (medscape.com)
Assessment of responses to polysaccharide antigens is important in patients older than 18-24 months because these responses may be deficient in some patients who can respond normally to protein antigens. (medscape.com)
Therefore, antibody responses should be measured to polysaccharide antigens that are not present in the protein-conjugated pneumococcal vaccine. (medscape.com)

In addition, the BAFF-R-directed CAR T cells targeted CRISPR-modified human leukemia cells that lacked CD19. (ajmc.com)
CD19 appears to be expressed on myeloid leukemia cells, particularly those of monocytic lineage. (thermofisher.com)

CD19 expression is even maintained in B lineage cells that undergo neoplastic transformation. (wikipedia.org)
A two-parameter pseudocolor density plots showing the correlated expression of CD19 (or Ig Isotype control staining) versus side light-scatter (SSC) signals was derived from gated events with the forward and side light-scatter characteristics of intact leucocytes. (bdbiosciences.com)
Sarah Larson , M.D. principal investigator and associate clinical professor of medicine, David Geffen School of Medicine at University of California, Los Angeles added, "While CD19 CAR T-cell therapies have transformed the lymphoma treatment landscape, durability has been limited by treatment resistance due to selective pressure against the target antigen and subsequent loss of expression. (mystateline.com)

The application of antigen receptor gene rearrangement of BIOMED-2 in the pathologic diagnosis of 348 cases with non-Hodgkin lymphoma in a single institution in Southwest of China. (cdc.gov)

We used T cells that were retrovirally transduced with this CAR to treat mice bearing a syngeneic lymphoma that naturally expressed the self-antigen murine CD19. (ashpublications.org)
One infusion of anti-CD19-CAR-transduced T cells completely eliminated normal B cells from mice for at least 143 days. (ashpublications.org)
Using a loss of function approach, researchers found reduced MYC levels in B cells of CD19 knockdown mice. (wikipedia.org)

Other CAR T cells usually only target 1 antigen. (cancer.net)

The following product was used in this experiment: CD19 Monoclonal Antibody (HIB19), PE, eBioscience™ from Thermo Fisher Scientific, catalog # 12-0199-42, RRID AB_1834376. (thermofisher.com)
Flow cytometry analysis of CD19 was performed by staining Raji CD19 Knock out cells with 0.25 µg Mouse IgG1 kappa Isotype Control (P3.6.2.8.1), PE, eBioscience™ (Product # 12-4714-82, yellow histogram) or 0.25 µg CD19 Monoclonal Antibody (HIB19), PE, eBioscience™ (Product # 12-0199-42, blue histogram). (thermofisher.com)

C57BL/6 mouse splenocytes were stained with CD19 (clone 6D5) PE/Dazzle™ 594 (filled histogram) or rat IgG2a, κ PE/Dazzle™ 594 isotype control (open histogram). (biolegend.com)

Approximately 80% of children have detectable antibodies to these antigens after 3 immunizations during their first year of life. (medscape.com)

CD19 is a crucial BCR-independent regulator of MYC-driven neoplastic growth in B cells since the CD19-MYC axis promotes cell expansion in vitro and in vivo. (wikipedia.org)

Hepatitis B is not a reliable antigen for testing immune competence because of the high frequency of nonresponders in the population, particularly in persons older than 40 years. (medscape.com)
The method entails isolating patient's immune cells (T cells) and genetically engineering them to recognize and kill cancer cells using a Chimeric Antigen Receptor (CAR). (lls.org)

Genes encoding CD19sIg fusion proteins were constructed by fusing either exons 1 to 3 (CD19sIg1-3) or exons 1 to 4 (CD19sIg1-4) of the human CD19 cDNA to a human IgG1Fc fragment. (escholarship.org)
Contrary to some early doubts, human plasma cells do express CD19, as confirmed by others. (wikipedia.org)
Left Plot) or BD Horizon™ R718 Mouse Anti-Human CD19 antibody (Cat. (bdbiosciences.com)
Human whole blood was stained with the BD Horizon™ BV605 Mouse Anti-Human CD19 antibody (Cat. (bdbiosciences.com)

Anatomy29

Organisms10

Diseases3

Chemicals and Drugs157

Analytical, Diagnostic and Therapeutic Techniques and Equipment27

Phenomena and Processes31

Disciplines and Occupations1

Information Science3

Health Care3

Receptors7

CD2011

Malignancies11

Anti-CD19 CAR-T cells1

Molecule6

Tumor15

Specificity3

Receptor-modified T cells1

Bone marrow5

Autologous1

CD214

Targets3

Immature B cells2

CD221

BCMA2

Cytokines1

Efficacy3

Follicular1

Differentiation4

Immunoglobulin4

Malignant6

Immunotherapy1

Acute lymphobl4

Therapy13

Recognition4

Transmembrane2

Lymphoma cells2

Ultimately1

Peripheral1

Knockout3

Tyrosine1

Relapse1

Humans3

Extracellular1

Experiments1

Proliferation1

ScFv1

Protein7

Leukemia cells2

Expression3

Gene1

Mice3

Target1

HIB192

Histogram1

Approximately1

Vitro1

Immune2

Human4